Education Blog for Healthcare Professionals

ASH 2014 Highlights: Thrombosis and Anticoagulation

| Comments Off

Stephan Moll, MD writes... The annual American Society of Hematology (ASH) meeting took place in Dec 2014 in San Francisco.  A summary of the clinically relevant thrombosis and anticoagulation presentation and abstracts is presented here (Top 10 ASH Highlights).


Disclosure: I have been a consultant to Portola, Daiichi, Janssen, and Boehringer-Ingelheim. 

Last updated: Jan 27th, 2015

Fourth NOAC FDA Approved for DVT, PE and Atrial Fibrillation: Savaysa (Edoxaban)

| Comments Off

Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release  is here (link).  Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The detailed drug package insert with dosing information is here (link). Read the rest of this entry »

Two Things Physicians Should Avoid

| Comments Off

Stephan Moll, MD writes (Dec 17, 2014)…  The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1]. Read the rest of this entry »

VTE Prophylaxis in Hospitalized Patients: Guidance Document

| Comments Off

Stephan Moll, MD writes (on 12/5/2014)… Venous thromboembolism (VTE) prophylaxis in hospitalized patients is important; it is also mandated by the Joint Commission [ref].  We have developed at the University of North Carolina (UNC) a guidance document (link here; UNC VTE prophylaxis guidance document) as a resource for our health care professionals to assist in making evidence-based decisions on which patients to give what type of VTE prophylaxis.

Recommendations provided in this document are a reflection of current guidelines, clinical evidence, and UNC institutional initiatives, but are not intended to replace clinical judgment or patient evaluation.  Readers are welcome to use this document for their institution or practice – using it as is or modifying it.


Joint Commission VTE measures (link here)

Disclosures: None

Last updated: Dec 5th, 2014

Aspirin Decreases Recurrent DVT and PE

| Comments Off

Stephan Moll, MD writes… Aspirin is beneficial in preventing recurrent venous thromboembolism (VTE) in patients who have had a previous episode of unprovoked VTE and who have been treated with anticoagulant therapy, a publication in the journal Circulation re-confirms this week: Aspirin reduces the risk of recurrent VTE by more than a third without significantly increasing the risk of bleeding [ref 1].  This publication does not report results of a new study, but is rather a further analysis of the previously published WARFASA and ASPIRE aspirin trials [ref 2,3]. Read the rest of this entry »

Is acupuncture safe for anticoagulated patients?

| Comments Off

Beth Waldron, Clot Connect program director writes…

Background:  Anticoagulant and anti-platelet drugs increase bleeding risk.  Patients taking these drugs are typically advised to avoid activities which might cause increased bleeding, bruising or trauma.

Acupuncture involves the insertion of thin needles through the skin at strategic points along the body. These needles are very thin, much smaller than the hypodermic needles used for phlebotomy and injections.(Ref 1)   Because the needles used are so small, very little bleeding occurs with acupuncture. (2)

The data:

  • A 2014 published study on the safety of acupuncture for patients taking anticoagulant or anti-platelet medications found no reports of major bleeding.(3)  Minor ‘microbleeding’—defined as bleeding which stopped within 30 seconds—occurred in only slightly more patients taking an anticoagulant (4.8%) than patients not on an anticoagulant (3.0%).  Patients taking an anti-platelet medication had very little bleeding (0.9%).
  • There was also no significant difference in the amount of bruising which occurred from acupuncture between those taking an anticoagulant (2.0%) or an anti-platelet (1.6%) and those who took neither (1.3%).
  • An earlier study of acupuncture among hospitalized patients taking warfarin, also found very little bleeding and that a higher INR value did not predict a higher risk of  bleeding–bleeding incidence after acupuncture were no different among patients with a low INR (14.6%) and those with a high INR (14.3%). (4)

Summary:   Acupuncture appears to be safe for the patient on an anticoagulant or anti-platelet medication.  However as a precaution, patients should inform their acupuncture provider in advance of the procedure of their medications so they can be alert and prepared.



1. UpToDate

2. “A Guide to Integrative Oncology”  University of Washington

3. Kim et al. The safety of acupuncture treatments for patients taking warfarin or antiplatelet medications: A retrospective chart review study European Journal of Integrative Medicine, May 17, 2014.

4. Miller et al. Acupuncture treatment for hospitalized patients on anticoagulant therapy—a safety study  BMC Complementary and Alternative Medicine 2012 (Suppl 1) p 107